These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 33688737)
21. Structure-Activity Relationships of [des-Arg Ramos-Colon CN; Lee YS; Remesic M; Hall SM; LaVigne J; Davis P; Sandweiss AJ; McIntosh MI; Hanson J; Largent-Milnes TM; Vanderah TW; Streicher J; Porreca F; Hruby VJ J Med Chem; 2016 Nov; 59(22):10291-10298. PubMed ID: 27797517 [TBL] [Abstract][Full Text] [Related]
22. Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin. Joshi AA; Murray TF; Aldrich JV J Med Chem; 2015 Nov; 58(22):8783-95. PubMed ID: 26491810 [TBL] [Abstract][Full Text] [Related]
23. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2. Vig BS; Zheng MQ; Murray TF; Aldrich JV J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053 [TBL] [Abstract][Full Text] [Related]
24. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors. Aldrich JV; Zheng QI; Murray TF Chirality; 2001; 13(3):125-9. PubMed ID: 11270320 [TBL] [Abstract][Full Text] [Related]
25. Effects of modifications of residues in position 3 of dynorphin A(1-11)-NH2 on kappa receptor selectivity and potency. Lung FD; Meyer JP; Lou BS; Xiang L; Li G; Davis P; DeLeon IA; Yamamura HI; Porreca F; Hruby VJ J Med Chem; 1996 Jun; 39(13):2456-60. PubMed ID: 8691442 [TBL] [Abstract][Full Text] [Related]
26. Prediction of the conformational requirements for binding to the kappa-opioid receptor and its subtypes. I. Novel alpha-helical cyclic peptides and their role in receptor selectivity. Collins N; Hruby VJ Biopolymers; 1994 Sep; 34(9):1231-41. PubMed ID: 7948735 [TBL] [Abstract][Full Text] [Related]
27. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting. Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155 [TBL] [Abstract][Full Text] [Related]
28. Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors. Przydzial MJ; Pogozheva ID; Ho JC; Bosse KE; Sawyer E; Traynor JR; Mosberg HI J Pept Res; 2005 Nov; 66(5):255-62. PubMed ID: 16218993 [TBL] [Abstract][Full Text] [Related]
29. Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration. Perlikowska R; Piekielna J; Gentilucci L; De Marco R; Cerlesi MC; Calo G; Artali R; Tömböly C; Kluczyk A; Janecka A Eur J Med Chem; 2016 Feb; 109():276-86. PubMed ID: 26785295 [TBL] [Abstract][Full Text] [Related]
30. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor. Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963 [TBL] [Abstract][Full Text] [Related]
32. Development of highly potent and selective dynorphin A analogues as new medicines. Lung FD; Chen CH; Liu JH J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994 [TBL] [Abstract][Full Text] [Related]
33. Species differences in the effects of the κ-opioid receptor antagonist zyklophin. Sirohi S; Aldrich JV; Walker BM Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699 [TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11. Meyer JP; Collins N; Lung FD; Davis P; Zalewska T; Porreca F; Yamamura HI; Hruby VJ J Med Chem; 1994 Nov; 37(23):3910-7. PubMed ID: 7966152 [TBL] [Abstract][Full Text] [Related]
35. Development of a Selective Peptide κ-Opioid Receptor Antagonist by Late-Stage Functionalization with Cysteine Staples. Muratspahić E; White AM; Ciotu CI; Hochrainer N; Tomašević N; Koehbach J; Lewis RJ; Spetea M; Fischer MJM; Craik DJ; Gruber CW J Med Chem; 2023 Sep; 66(17):11843-11854. PubMed ID: 37632447 [TBL] [Abstract][Full Text] [Related]
36. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic. Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094 [TBL] [Abstract][Full Text] [Related]